U.S., Aug. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07124117) titled 'A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors' on Aug. 04.
Brief Summary: This is a 2-part trial: Part A (Dose Escalation) is designed to establish the maximum tolerated dose (MTD) and putative recommended phase 2 dose of OBI-902 (study drug) as monotherapy. Part B (Cohort Expansion) is intended to determine the optimal RP2D and further characterize the safety and preliminary clinical activity profile of the OBI-902 RP2D in participants with advanced solid tumors.
Study Start Date: Aug. 11
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
DRUG: OBI-902
OBI-902 is an antibody-drug...